NCT03747965Unknown1 期
Phase I Study of CRISPR-Cas9 Mediated PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning Regimen of Paclitaxel and Cyclophosphamide in Mesothelin Positive Multiple Solid Tumors
Chinese PLA General Hospital1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2018年11月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Study of related adverse events
研究概览
简要总结
Multiple solid tumors have positive targets of mesothelin expressed on the surfaces of the tumor cells, the investigators use the technique of CRISPR-Cas9 to knocked out the PD-1 of the chimeric antigen receptor (CAR) T cells with the combination of Pretreatment by Paclitaxel and Cyclophosphamideto to effect the immuno-microenvironment around tumors.
详细描述
- To evaluate the feasibility and safety of CRISPR-Cas9 mediated PD-1 gene-knocked out chimeric antigen receptor (CAR) T cells in patients with mesothelin positive multiple solid tumors.
- To evaluate the duration and in vivo persistence of transferred CAR-T cells.
- To observe and measure anti-tumor responses for patients with detectable mesothelin positive tumor lesions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed with mesothelin positive multiple solid tumors, especially in Pancreatic cancer, cholangiocarcinoma cancer and ovarian cancer .
- •Failure of at least one prior standard of care chemotherapy for advanced stage disease.
- •Subjects must have measureable disease as defined by RECIST 1.1 criteria or modified RECIST criteria.
- •Patients > 18 years of age.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Life expectancy > 12 weeks.
- •Satisfactory organ and bone marrow function as defined by the following (of note, the minimal blood counts should be in the absence of transfusion or cytokine support):
- •i.Absolute neutrophil count > 1,000/μl ii.Platelets >75,000/μl iii.Hemoglobin > 9 g/dL iv.Bilirubin < 2 times of the institutional normal upper limit unless secondary to bile duct obstruction by tumor v.Creatinine < 1.5 times of the institutional normal upper limit vi.Albumin ≥2 vii.Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5 times of the institutional normal upper limit viii.Cardiac ejection fraction of >45% as measured by resting echocardiogram, with no significant pericardial effusion ix.Normal lung function
- •Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤ 1.5 and a PTT < 1.2 times of the upper limit of normal unless the patient is therapeutically anti-coagulated for history of cancer-related thrombosis and has stable coagulation parameters.
- •Ability to understand and the willingness to provide written informed consent.
- •Male and Female subjects of reproductive potential agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) and abstain from other methods of conception during the study and for 6 months following the study cell infusion or proof of sterility.
排除标准
- •Patients with moderate or higher hydrothorax and abdominal effusion, which are difficult to control by conventional treatment and require continuous catheter drainage;
- •Either of the following virological tests is positive: HIV;HCV.HBsAg;Positive HBV DNA copy number was detected simultaneously (quantitative detection was 5 x 10^2 copies/ml).RPR or TPPA positive;
- •Other malignant tumors, with the exception of basal cell carcinoma of the skin, superficial cervical cancer, bladder cancer, and prostate cancer(PSA value < 1.0) that do not require further treatment;
- •Accompanied by central metastasis;
- •Severe, uncontrollable comorbidities that may affect program compliance or interpretation of interference results, or any serious medical conditions that may affect the safety of the subject (such as uncontrollable heart disease, hypertension, active virus, bacterial infection or uncontrollable systemic fungal infection);
- •Active autoimmune diseases (including but not limited to systemic lupus erythematosus, sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.) need to be treated with immunosuppressive therapy within 4 weeks before enrollment, with the exception of thyroid hormone replacement therapy;
- •Subjects are receiving immunosuppressive, glucocorticoid (systemic or local) therapy (dose >10mg/ day prednisone or other equivalent hormones), and continue to use it within 2 weeks before enrollment;
- •With the history of organ transplantation;
- •Subjects who were given the last treatment less than 4 weeks before the initial treatment or participated in other relevant clinical study subjects at the same time;
- •With the history of gene therapy;
- •During the period of first study, live vaccines were administered within 4 weeks before PBMC collection;
- •People who have a history of psychotropic drug abuse and are unable to get rid of it or have a history of mental disorders;
- •Life-threatening allergic, hypersensitive, or intolerant reactions to GC008t preparations or their excipients (including DMSO) are known;
- •Hemorrhagic and thrombotic tendencies:3 months prior to study drug treatment for the first time there have been significant clinical significance of bleeding symptoms or have a definite bleeding tendency, such as gastrointestinal bleeding, bleeding ulcers, coagulant function abnormality (PT > 16 s, APTT, TT > > 43 s 21 s, FIB < 2 g/L), there is tendency of inherited or acquired bleeding and thrombosis (such as hemophilia, blood coagulation dysfunction, thrombocytopenia, the splenic function, etc.), were treated with thrombolysis and anticoagulation, 6 months prior to study drug treatment for the first time move/enous thromboembolism events,Such as cerebral vascular diseases (including cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;
- •Other severe, acute or chronic medical or mental illnesses that may increase the risk of participating in the study or may interfere with the interpretation of the results, according to the researchers.
研究组 & 干预措施
Mesothelin-directed CAR-T cells infusion
Experimental
Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard "3+3" dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
干预措施: Mesothelin-directed CAR-T cells (Biological)
结局指标
主要结局
Study of related adverse events
时间窗: 24 weeks
Grade 3 or severer signs/symptoms, toxicities and clinical
次要结局
- Clinical responses of mesothelin-directed CAR T cells infusion(24 weeks)
研究者
Han weidong
Director
Chinese PLA General Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.Solid Tumor, AdultNCT03545815Chinese PLA General Hospital10
已完成
1 期
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid TumorsNeoplasms With Mesothelin ExpressionEpithelioid MesotheliomaCholangiocarcinoma, ExtrahepaticAdenocarcinoma, PancreaticNCT04034238National Cancer Institute (NCI)19
已完成
不适用
Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian CancerOvarian CancerNCT05372692Weijia Fang, MD3
已完成
1 期
Immunotoxin Therapy in Treating Patients With Advanced Solid TumorsFallopian Tube CancerHead and Neck CancerMalignant MesotheliomaPrimary Peritoneal Cavity CancerLung CancerCervical CancerOvarian CancerPancreatic CancerNCT00066651National Cancer Institute (NCI)
已完成
不适用
Mesothelin expression in gastrointestinal carcinomasJPRN-UMIN000017317Hokkaido University School of Medicine100